W20 acquires data technology firms Swoop and IPM.aiW20 has begun 2021 by buying data technology firms Swoop and IPM.ai, adding to its rapidly growing list Share XW20 acquires data technology firms Swoop and IPM.aihttps://pharmaphorum.com/news/w20-acquires-data-technology-firms-swoop-and-ipm-ai/
Fishawack Health acquires The Hive Health GroupUK comms agency Fishawack Health has acquired The Hive Health Group and its two brands Hive Health and Share XFishawack Health acquires The Hive Health Grouphttps://pharmaphorum.com/news/fishawack-health-acquires-the/
Itamar buys Spry to add wearable to its sleep apnoea detectorsIsraeli company Itamar Medical has agreed to acquire Spry Health, aiming to use the US company’s wearable technology Share XItamar buys Spry to add wearable to its sleep apnoea detectorshttps://pharmaphorum.com/news/itamar-buys-spry-to-add-wearable-to-its-sleep-apnoea-detectors/
European telehealth firm HealthHero buys MyClinic.ieEuropean telehealth firm HealthHero has bought MyClinic.ie, a rival based in the Republic of Ireland. Already a major Share XEuropean telehealth firm HealthHero buys MyClinic.iehttps://pharmaphorum.com/news/european-telehealth-firm-healthhero-buys-myclinic-ie/
Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
Bioclinica boosts digital trial credentials with Saliency buyWith the ink barely dry on its last merger agreement, clinical trial and imaging specialist Bioclinica is on Share XBioclinica boosts digital trial credentials with Saliency buyhttps://pharmaphorum.com/news/bioclinica-boosts-digital-trial-credentials-with-saliency-buy/
Angelini and Arvelle create neurology player with $960m mergerThere’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Share XAngelini and Arvelle create neurology player with $960m mergerhttps://pharmaphorum.com/news/angelini-and-arvelle-create-neurology-player-with-960m-merger/
BMS/Celgene merger payout evaporates as CVR deadline passesFormer Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three Share XBMS/Celgene merger payout evaporates as CVR deadline passeshttps://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bnFrench pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise Share XServier beefs up in cancer, buying Agios’ oncology business for $1.8bnhttps://pharmaphorum.com/news/servier-cancer-agios-oncology/
